NYSEAMERICAN:ARMP

Armata Pharmaceuticals (ARMP) Stock Forecast, Price & News

$1.57

0.00 (0.00%)

(As of 06/7/2023 ET)

Compare

Today's Range: $1.50
▼
$1.57
50-Day Range: N/A
52-Week Range: $0.83
▼
$4.92

Volume: 1,879 shs
Average Volume: 9,360 shs
Market Capitalization: $56.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Short Interest Social Media

Armata Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 345.9% Upside
$7.00 Price Target
Short Interest: Healthy
0.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.32) to ($0.35) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Armata Pharmaceuticals has a forecasted upside of 345.9% from its current price of $1.57.
Amount of Analyst Coverage
Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.20% of the float of Armata Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Armata Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Armata Pharmaceuticals has recently decreased by 41.76%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Armata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Armata Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARMP.

2.1

News and Social Media Coverage

News Sentiment
Armata Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
80.10% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.76% of the stock of Armata Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.32) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Armata Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Armata Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Armata Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Receive ARMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARMP Stock News Headlines

May 31, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Armata Pharmaceuticals (ARMP) Buy Recommendation

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 12, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 11, 2023 | seekingalpha.com

Armata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79M

May 11, 2023 | finance.yahoo.com

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

May 11, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 9, 2023 | americanbankingnews.com

Armata Pharmaceuticals (ARMP) Set to Announce Earnings on Wednesday

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

May 9, 2023 | americanbankingnews.com

Armata Pharmaceuticals (ARMP) Scheduled to Post Quarterly Earnings on Wednesday

April 6, 2023 | uk.finance.yahoo.com

Armata Pharmaceuticals, Inc. (ARMP)

March 21, 2023 | americanbankingnews.com

Armata Pharmaceuticals, Inc. to Post Q1 2023 Earnings of ($0.29) Per Share, HC Wainwright Forecasts (NYSEAMERICAN:ARMP)

March 17, 2023 | finanznachrichten.de

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

March 16, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

March 6, 2023 | marketwatch.com

Armata Pharma Shares Up 24% After Positive Cystic Fibrosis Therapeutic Trial Data

March 6, 2023 | msn.com

Armata Surges on Promising Data in Lung Infection

March 6, 2023 | msn.com

Armata surges 15% as inhaled bacterial infection drug shows promise in lung disorder patients

March 6, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)

March 6, 2023 | markets.businessinsider.com

Armata Pharma Presents Positive Topline Data For Lead Multi-phage Candidate, AP-PA02

March 6, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

January 10, 2023 | finance.yahoo.com

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

December 22, 2022 | finance.yahoo.com

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

December 8, 2022 | finance.yahoo.com

Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

November 28, 2022 | finance.yahoo.com

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

November 28, 2022 | finance.yahoo.com

After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)

November 15, 2022 | finance.yahoo.com

Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing

November 9, 2022 | finance.yahoo.com

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

See More Headlines

ARMP Price History

30 days | 90 days | 365 days | Advanced Chart

ARMP Company Calendar

Last Earnings: 5/11/2023
Today: 6/07/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:ARMP
CUSIP: N/A
CIK: N/A
Web: www.armatapharma.com
Phone: (310) 655-2928
Fax: 310-665-2963
Employees: 69
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +345.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,920,000.00
Net Margins: -841.24%
Pretax Margin: -841.22%
Return on Equity: -108.35%
Return on Assets: -42.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.75
Quick Ratio: 0.75

Sales & Book Value

Annual Sales: $5.51 million
Price / Sales: 10.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.00 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 36,150,000
Free Float: 7,193,000
Market Cap: $56.76 million
Optionable: Not Optionable
Beta: 1.17

Key Executives

Brian C. Varnum
Chief Executive Officer & Director

Duane A. Morris
Vice President-Operations

Julianne Averill
Chief Financial & Accounting Officer

Mina Pastagia
Chief Medical Officer

Bryan Kadotani
Vice President-Program Management & Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ARMP Stock - Frequently Asked Questions

Should I buy or sell Armata Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARMP shares.
View ARMP analyst ratings or view top-rated stocks.
What is Armata Pharmaceuticals' stock price forecast for 2023?: 1 brokers have issued 12-month price objectives for Armata Pharmaceuticals' shares. Their ARMP share price forecasts range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price.
View analysts price targets for ARMP or view top-rated stocks among Wall Street analysts.
Are investors shorting Armata Pharmaceuticals?: Armata Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 21,900 shares, a drop of 41.8% from the April 30th total of 37,600 shares. Based on an average daily volume of 12,900 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.2% of the company's shares are sold short.
View Armata Pharmaceuticals' Short Interest.
When is Armata Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ARMP earnings forecast.
How were Armata Pharmaceuticals' earnings last quarter?: Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.11. The firm earned $0.80 million during the quarter, compared to the consensus estimate of $1.50 million. Armata Pharmaceuticals had a negative net margin of 841.24% and a negative trailing twelve-month return on equity of 108.35%.
What other stocks do shareholders of Armata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

What is Armata Pharmaceuticals' stock symbol?: Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."
Who are Armata Pharmaceuticals' major shareholders?: Armata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.17%), HRT Financial LP (0.09%) and Simplex Trading LLC (0.00%).
View institutional ownership trends.
How do I buy shares of Armata Pharmaceuticals?: Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Armata Pharmaceuticals' stock price today?: One share of ARMP stock can currently be purchased for approximately $1.57.
How much money does Armata Pharmaceuticals make?: Armata Pharmaceuticals (NYSEAMERICAN:ARMP) has a market capitalization of $56.76 million and generates $5.51 million in revenue each year. The company earns $-36,920,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.
How can I contact Armata Pharmaceuticals?: Armata Pharmaceuticals' mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The official website for the company is www.armatapharma.com. The company can be reached via phone at (310) 655-2928, via email at jallaire@lifesciadvisors.com, or via fax at 310-665-2963.

This page (NYSEAMERICAN:ARMP) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial